21,500 Shares in scPharmaceuticals Inc. (NASDAQ:SCPH) Purchased by FNY Investment Advisers LLC
FNY Investment Advisers LLC bought a new stake in scPharmaceuticals Inc. (NASDAQ:SCPH – Get Rating) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,500 shares of the company’s stock, valued at approximately $154,000. FNY Investment Advisers LLC owned about 0.08% of scPharmaceuticals at the end of the most recent reporting period.
→ Buy THIS stock before Taiwan is attacked (From Behind the Markets)
Other institutional investors and hedge funds also recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in scPharmaceuticals during the second quarter valued at about $53,000. Cubist Systematic Strategies LLC purchased a new position in shares of scPharmaceuticals during the 3rd quarter valued at $75,000. State Street Corp raised its holdings in shares of scPharmaceuticals by 15.0% in the 2nd quarter. State Street Corp now owns 17,360 shares of the company’s stock valued at $84,000 after acquiring an additional 2,260 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in scPharmaceuticals in the 3rd quarter worth approximately $92,000. Finally, Ritholtz Wealth Management purchased a new position in scPharmaceuticals in the 3rd quarter worth approximately $98,000. Hedge funds and other institutional investors own 53.90% of the company’s stock.
scPharmaceuticals Stock Performance
Shares of scPharmaceuticals stock traded down $0.12 during midday trading on Friday, hitting $7.11. The company had a trading volume of 65,093 shares, compared to its average volume of 554,004. The company has a 50 day moving average of $7.22 and a 200 day moving average of $6.36. scPharmaceuticals Inc. has a 52-week low of $3.68 and a 52-week high of $10.38.
Analyst Ratings Changes
Several analysts have issued reports on SCPH shares. Cowen started coverage on scPharmaceuticals in a research note on Thursday, December 1st. They issued an “outperform” rating and a $25.00 target price for the company. SVB Leerink raised their target price on shares of scPharmaceuticals from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, January 27th. Finally, Cowen assumed coverage on shares of scPharmaceuticals in a research report on Thursday, December 1st. They issued an “outperform” rating and a $25.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $18.00.
scPharmaceuticals Company Profile
scPharmaceuticals, Inc engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider scPharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and scPharmaceuticals wasn’t on the list.
While scPharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
